Eli Lilly (NYSE: LLY) plans to acquire Merida Biosciences to expand its autoimmune and allergic disease pipeline, including lead candidate MER511. The deal is expected to add early stage precision immunology assets to Lilly's existing portfolio in metabolic and neurology treatments. New Phase 3b TOGETHER trial data report durable 52 week efficacy for a Taltz and Zepbound combination in patients with psoriatic disease and obesity. The dual therapy approach targets both psoriatic disease...

Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya...

In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.

Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026. The acquisition expands Lilly’s immunology pipeline and gives it access to Merida’s antibody-engineering platform, which is […]

Obesity/GLP-1 drug market heats up as oral pills scale and new injectables emerge.

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Podcast guest Serafino Fabiano details Eli Lilly’s $3 billion Kenosha injectable medicine site, new jobs and Wisconsin’s role in global drug production.

Eli Lilly (NYSE:LLY) is in focus after a current corporate update, with sector conditions and broader market themes framing discussion around the company today today.

Eli Lilly reported Phase 3b data showing Taltz plus Zepbound improved disease control and weight loss outcomes in psoriasis and psoriatic arthritis...

The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.

Eli Lilly has agreed to acquire Merida Biosciences for up to $2.875 billion to gain a precision autoantibody degradation platform led by MER511.

Eli Lilly agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, marking its 13th deal of 2026 as it deploys…